Fasoracetam for ADHD

Fasoracetam (NFC-1, AEVI-001) is a racetam.
Fasoracetam is a non-stimulatory modulator (agonist) of all 3 groups of metabotropic glutamate receptors.
Fasoracetam is bioavailable when taken orally and is largely excreted unchanged in the urine.

In studies with rodents, it improved cognitive functions.
Fasoracetam was unsuccessful in Phase 3 trials for the treatment of vascular dementia. Studies in primates and rodents found no signs of dependence or addiction.¹

Fasoracetam may be effective in the treatment of ADHD in people with certain mGluR mutations. This applies to around 10% of all ADHD cases. In all other cases, fasoracetam is probably ineffective.
A 5-week, open-label, single-blind, placebo-controlled and registered study in 30 adolescents aged 12-17 years with ADHD and mutations in mGluR network genes showed a significant improvement in ADHD symptoms without increased side effects.²
Two other registered studies found no improvement in ADHD symptoms in those with and without glutamate receptor gene mutations.³